| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $15.35B | +3.6% |
| Cost of Revenue | $6.82B | +1.3% |
| Gross Profit | $8.53B | +5.6% |
| R&D Expense | $70.0M | +6.1% |
| SG&A Expense | $5.01B | +2.1% |
| Operating Income | $2.59B | -18.8% |
| Pre-tax Income | $1.91B | -30.6% |
| Income Tax | $473.0M | -17.9% |
| Net Income | $1.44B |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $510.0M | +91.0% |
| Accounts Receivable | $1.50B | +9.8% |
| Inventory | $1.30B | +13.7% |
| Current Assets | $4.00B | +18.4% |
| Total Assets | $53.43B | +2.5% |
| Current Liabilities | $8.09B | -9.3% |
| Long-term Debt | $12.91B | +29.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $2.22B | +67.0% |
| Capital Expenditures | $563.0M | +32.5% |
| Investing Cash Flow | -$1.61B | -105.9% |
| Financing Cash Flow | -$223.0M | +73.2% |
| Free Cash Flow | $1.66B | +83.2% |
| -33.9% |
| EPS (Basic) | $1.06 | -32.1% |
| EPS (Diluted) | $1.05 | -32.3% |
| Total Liabilities |
| $29.19B |
| +10.3% |
| Stockholders' Equity | $24.24B | -5.6% |